[1]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152-156+193.[doi:10.3969/j.issn.1671-7414.2024.03.026]
　NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(03):152-156+193.[doi:10.3969/j.issn.1671-7414.2024.03.026]
点击复制

帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
152-156+193
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment
文章编号:
1671-7414（2024）03-152-06
作者:
牛荣荣; 宋世雄; 宋 蕾
（邯郸市中医院脑病一科 河北邯郸 056000）
Author(s):
NIU Rongrong;  SONG Shixiong;  SONG Lei
（Department 1 of Brain Disease,Handan Traditional Chinese Medicine Hospital,Hebei Handan 056000, China）
关键词:
成纤维细胞生长因子22; CXC 型趋化因于配体16; 帕金森病; 认知障碍
分类号:
R744.8；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.03.026
文献标志码:
A
摘要:
目的 探讨帕金森病（Parkinson’s disease，PD）患者血清成纤维细胞生长因子22（fibroblast growth factor22，FGF22）和CXC 型趋化因子配体16（CXC chemokine ligand 16，CXCL16）水平检测对认知障碍的诊断价值。方法 选取2022 年6 月~2023 年6 月邯郸市中医院收治的PD 患者125 例作为研究对象，并根据PD 患者是否发生认知功能障碍，将其分为认知障碍未发生组（n=38）和认知障碍发生组（n=87）。采用酶联免疫吸附（ELISA）法测定各组血清FGF22，CXCL16 水平。采用Spearman 相关性分析血清FGF22，CXCL16 表达水平与帕金森综合评分量表（unified Parkinson’s disease rating scale,UPDRS）及蒙特利尔认知评估量表（Montreal Cognitive assessment，MoCA）评分之间的相关性。采用多因素Logistic 回归分析影响PD 患者认知障碍的因素。采用受试者工作特征（ROC）曲线分析FGF22，CXCL16 对PD 患者认知障碍的诊断效能。结果 相比于认知障碍未发生组，认知障碍发生组血清FGF22 表达水平(184.16±14.62ng/ml vs 203.24±12.15ng/ml) 显著降低（t=7.048），CXCL16 表达水平显著升高(2.59±0.46ng/ml vs2.06±0.34ng/ml)（t=6.376），UPDRS评分(41.43±5.62 分vs 32.46±4.28 分）显著升高（t=8.782），MoCA评分(23.91±3.14分 vs 26.54±2.31 分）显著减低（t=4.640），差异具有统计学意义（均P<0.001）。根据Spaerman 相关性分析得知，血清FGF22 表达水平与UPDRS 评分呈负相关（r=-0.435，P<0.05），与MoCA 评分呈正相关（r=0.742，P<0.05）；血清CXCL16 表达水平与UPDRS 评分呈正相关（r=0.532，P<0.05），与MoCA 评分呈负相关（r=-0.623，P<0.05）。多因素Logistic 分析显示，FGF22，MoCA 评分是影响PD 患者认知障碍的保护因素（P<0.05），CXCL16，UPDRS 评分是影响PD 患者认知障碍的危险因素（P<0.05）；血清FGF22，CXCL16 联合诊断PD 患者认知障碍的AUC 优于各自单独诊断（Z=2.919，2.437，P=0.003，0.015），敏感度和特异度分别为93.10% 和73.68%。结论 血清FGF22，CXCL16 水平与PD 患者认知障碍密切相关，两者联合可更好地诊断PD 患者是否发生认知障碍。
Abstract:
Objective To explore the diagnostic value of serum levels of fibroblast growth factor 22 (FGF22) and CXC chemokine ligand 16 (CXCL16) in patients with Parkinson’s disease (PD) in cognitive impairment. Methods A total of 125 PD patients admitted to Handan Traditional Chinese Medicine Hospital from June 2022 to June 2023 were selected as the research subjects, and they were separated into a non cognitive impairment group (n=38) and a cognitive impairment group (n=87) based on whether they had cognitive impairment. Enzyme-linked immunosorbent assay (ELISA) was applied to determine the levels of serum FGF22 and CXCL16 in each group. Spearman correlation was applied to analyze the correlation among serum FGF22 and CXCL16 expression levels, Unified Parkinson’s Disease Rating Scale (UPDRS) and Montreal Cognitive Assessment (MoCA) scores. Multivariate logistic regression was applied to analyze the factors affecting cognitive impairment in PD patients. Receiver operating characteristic (ROC) curve was applied to analyze the diagnostic efficacy of FGF22 and CXCL16 for cognitive impairment in PD patients. Results Compared with the non cognitive impairment group, the expression level of serum FGF22 (184.16±14.62ng/ml vs 203.24±12.15ng/ml) in cognitive impairment group and the MoCA score(23.91±3.14 分 vs 26.54±2.31 分） were decreased (t=7.048, 4.460, all P<0.05), while the expression levels of CXCL16 (2.59±0.46ng/ml vs 2.06±0.34ng/ml)and the UPDRS score(41.43±5.62 score vs 32.46±4.28 score) were increased (t=6.376,8.782,all P<0.05),and the differences were statisaically significant.According to Spearman correlation analysis, the expression level of serum FGF22 was negatively correlated with UPDRS score (r=-0.435, P<0.05), but positively correlated with MoCA score (r=0.742, P<0.05). The expression level of CXCL16 in serum was positively correlated with UPDRS score (r=0.532, P<0.05), but negatively correlated with MoCA score (r=-0.623, P<0.05). Multivariate logistic analysis showed that FGF22 and MoCA scores were protective factors for cognitive impairment in PD patients (all P<0.05), while CXCL16 and UPDRS scores were risk factors for cognitive impairment in PD patients (all P<0.05). The combination of serum FGF22 and CXCL16 in the diagnosis of cognitive impairment in PD patients had better AUC than their respective alone diagnoses (Z=2.919,2.437, P=0.003,0.015), with a sensitivity and a specificity of 93.10% and 73.68%, respectively. Conclusion The levels of serum FGF22 and CXCL16 were closely related to cognitive impairment in PD patients, and the combination of the two could better diagnose whether PD patients have cognitive impairment.

参考文献/References:

[1] 李群英, 甄时建, 何树光, 等. 帕金森病患者治疗期间血清miR-153, miR-128b 水平表达与非运动症状的相关性研究[J]. 现代检验医学杂志, 2021, 36(5):120-123, 168. LI Qunying, ZHEN Shijian, HE Shuguang, et al. Research on correlation between expression of serum miR-153, miR-128b levels and non-motor symptoms in patients with Parkinson’s disease during treatment period[J]. Journal of Modern Laboratory Medicine,2021, 36(5): 120-123, 168.
[2] FANG Congong, L? Longqin, MAO Shanping, et al. Cognition deficits in Parkinson’s disease: mechanisms and treatment[J]. Parkinson’s Disease, 2020, 2020,2076942.
[3] HELY M A, RELD W G J, ADENA M A, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years[J]. Movement Disorders, 2008, 23(6): 837-844.
[4] 白雪, 董巧云, 赵丽, 等. 帕金森病患者血清miR-7和α-Syn 表达水平与认知功能障碍的相关性研究[J]. 现代检验医学杂志, 2023, 38(4): 78-82. BAI Xue, DONG Qiaoyun, ZHAO Li, et al. Correlation between serum miR-7 and α-Syn expression levels and cognitive impairment in patients with Parkinson’s disease[J]. Journal of Modern Laboratory Medicine,2023, 38(4): 78-82.
[5] 武冬冬, 杜危, 龙云飞, 等. 帕金森病患者主观认知减退的临床特征及其与情感症状的关系初探[J]. 中华神经科杂志, 2022, 55(3): 191-195. WU Dongdong, DU Wei, LONG Yunfei, et al. Clinical characteristics of subjective cognitive decline in patients with Parkinson’s disease and its relationship with affective symptoms: a preliminary study[J].Chinese Journal of Neurology, 2022, 55(3): 191-195.
[6] ZINKLE A, MOHAMMADI M. Structural biology of the FGF7 subfamily[J]. Frontiers in Genetics, 2019, 10:102.
[7] WU Yimi, SU Fengyun, KALYANA-SUNDARAM S,et al. Identification of targetable FGFR gene fusions in diverse cancers[J]. Cancer Discovery, 2013, 3(6): 636-647.
[8] 张茗, 郭翃江, 严之红, 等. 缺血性脑卒中后认知功能障碍老年患者血清神经丝轻链蛋白和CXC 型趋化因子配体16 水平变化及意义[J]. 中华实用诊断与治疗杂志, 2022, 36(5): 500-504. ZHANG Ming, GUO Hongjiang, YAN Zhihong, et al. Changes and significances of serum neurofilament light chain protein and CXC-chemokine ligand 16 in elderly patients with cognitive impairment after ischemic stroke[J]. Journal of Chinese Practical Diagnosis and Therapy, 2022, 36(5): 500-504.
[9] 刘军. 中国帕金森病的诊断标准(2016 版)[J]. 中华神经科杂志, 2016, 49(4): 268-271. LIU Jun. Diagnostic criteria of Parkinson’s disease in China (2016 edition)[J]. Chinese Journal of Neurology,2016, 49(4): 268-271.
[10] 蔡雪峰, 欧小凡, 黄宗文, 等. 参志胶囊联合多奈哌齐治疗帕金森的疗效及对脑神经递质和神经营养因子含量水平的影响[J]. 中药药理与临床, 2018,34(1): 170-174. CAI Xuefeng, OU Xiaofan, HUANG Zongwen, et al. Curative effect of Shenzhi capsules combined with donepezil on Parkinson’s disease and its effect on levels of brain neurotransmitters and neurotrophic factors[J].Pharmacology and Clinics of Chinese Materia Medica,2018, 34(1): 170-174.
[11] 李晓鹏, 赵鹏, 钱进. 血尿酸水平与初诊帕金森病轻度认知功能障碍相关性研究[J]. 神经损伤与功能重建, 2018, 13(11): 544-547. LI Xiaopeng, ZHAO Peng, QIAN Jin. Study on correlation between serum uric acid level and mild cognitive dysfunction in newly diagnosed Parkinson’s disease[J]. Neural Injury and Functional Reconstruction, 2018, 13(11): 544-547.
[12] 周小燕, 杨丹, 张敏, 等. 老年帕金森病患者血清PARK2, GFAP 和BDNF 表达对疾病分期和认知功能的评估[J]. 中国老年学杂志, 2023, 43(9): 2142-2145. ZHOU Xiaoyan, YANG Dan, ZHANG Min, et al. Evaluation of the expression of serum PARK2, GFAP and BDNF in elderly patients with Parkinson’s disease on disease staging and cognitive function[J]. Chinese Journal of Gerontology, 2023, 43(9): 2142-2145.
[13] 庞文渊, 翟利杰, 刘依琳, 等. 全球帕金森病综合治疗指南的分析[J]. 中国临床药理学杂志, 2022,38(21):2638-2643. PANG Wenyuan, ZHAI Lijie, LIU Yilin, et al. Analysis of global guidelines for comprehensive treatment of Parkinson’s disease [J]. China Journal of Clinical Pharmacology, 2022, 38(21): 2638-2643.
[14] 曹盼盼, 阎磊, 顾玥, 等. 颈动脉内中膜厚度增加与老年慢性肾脏病患者发生认知功能障碍的相关性[J]. 中华实用诊断与治疗杂志, 2019, 33(2): 124-127. CAO Panpan, YAN Lei, GU Yue, et al. Correlation between carotid intima-media thickness and cognitive impairment in elderly patients with chronic kidney disease[J]. Journal of Chinese Practical Diagnosis and Therapy, 2019, 33(2): 124-127.
[15] 刘志轩, 姜蕊. 帕金森病患者采用还原型谷胱甘肽治疗的临床效果及对患者UPDRS 评分的影响分析[J]. 罕少疾病杂志, 2022, 29(11): 104-105. LIU Zhixuan, JIANG Rui. Clinical effect of reduced glutathione on UPDRS score in patients with Parkinson’s disease[J]. Journal of Rare and Uncommon Diseases, 2022, 29(11): 104-105.
[16] 杨欢欢, 田海山, 李校堃, 等. 成纤维细胞生长因子22(FGF22) 的研究进展[J]. 中国生物工程杂志,2017, 37(5): 113-117. YANG Huanhuan, TIAN Haishan, LI Jiaokun, et al. The development of the study on fibroblast growth factor 22[J]. China Biotechnology, 2017, 37(5): 113-117.
[17] 徐宇浩, 韩薇, 徐建慧, 等. 首发性和复发性抑郁症伴认知功能障碍患者P300, 血清FGF22 水平的比较及其与认知功能、血清炎性因子的关系[J]. 中华神经医学杂志, 2022, 21(4): 354-358. XU Yuhao, HAN Wei, XU Jianhui, et al. Comparison of P300 and serum FGF22 levels between cognitive impairment patients with first-episode and recurrent depression and their relations with cognitive function and serum inflammatory factors[J]. Chinese Journal of Neuromedicine, 2022, 21(4): 354-358.
[18] 赵子洲, 莫煊, 郑银佳, 等. 首发抑郁症患者血清成纤维细胞生长因子22、胶质纤维酸性蛋白水平及其临床意义[J]. 现代生物医学进展, 2020, 20(20):3902-3906. ZHAO Zizhou, MO Xuan, ZHENG Yinjia, et al. Levels of serum fibroblast growth factor-22 and glial fibrillary acidic protein in patients with first-episode depression and its clinical significance[J]. Progress in Modern Biomedicine, 2020, 20(20): 3902-3906.
[19] ZAMAN V, SHIELDS D C, SHAMS R, et al. Cellular and molecular pathophysiology in the progression of Parkinson’s disease[J]. Metabolic Brain Disease, 2021,36(5): 815-827.
[20] AARSLAND D, BATZU L, HALLIDAY G M, et al. Parkinson disease-associated cognitive impairment[J].Nature Reviews Disease Primers, 2021, 7(1): 47.
[21] STOKOWSKA A, K?LL B L, BLOMSTRAND C,et al. Plasma neurofilament light chain levels predict improvement in late phase after stroke[J]. European Journal of Neurology, 2021, 28(7): 2218-2228.
[22] SCHRANZ D, MOLNAR T, ERDO-BONYAR S, et al. Fatty acid-binding protein 3 and CXC-chemokine ligand 16 are associated with unfavorable outcome in aneurysmal subarachnoid hemorrhage[J]. Journal of Stroke and Cerebrovascular Diseases, 2021, 30(11):106068.
[23] 朱学芳, 朱建建, 沈海清. 基于TLR4/NF-κB 信号通路及血清CXCL16,ACA 评价依达拉奉右莰醇对ACI 神经功能的保护作用[J]. 脑与神经疾病杂志,2023, 31(7): 401-406. ZHU Xuefang, ZHU Jianjian, SHEN Haiqing. Protective effect of edaravone dexbornol on neurological function in patients with acute cerebral infarction through TLR4/NF-κB signaling path signaling pathway and serum CXCL16, ACA[J].Journal of Brain and Nervous Diseases, 2023, 31(7):401-406.

备注/Memo

备注/Memo:
基金项目：河北省中医药管理局科研计划项目（2018393）。
作者简介： 牛荣荣 （1987-），女，硕士研究生，主治中医师，研究方向：神经内科帕金森病，E-mail：t56jcb@163.com。
通讯作者： 宋蕾 （1977-），女，本科，中西医结合副主任医师，研究方向：帕金森病，E-mail：n79gzp@163.com。
更新日期/Last Update: 2024-05-15